Analyst gives bullish assessment of Generex program

Rodman & Renshaw analyst Navdeep Jaikaria triggered a surge in the stock price of Generex Biotechnology with some bullish remarks on the sales potential of the company's late-stage oral insulin drug candidate. Late-stage trials of Oral-lyn for Type 1 diabetes are expected to get underway later in the year and Jaikaria expects that an approval could come in 2010. Potential sales of the drug were set at $600 million a year.

"We believe that Generex' Oral-lyn has advantages over other non-injectable insulin solutions," he said. "While many of these systems deliver insulin to the lungs and bronchial tree, Oral-lyn delivers insulin to the oral mucosa, avoiding the potential risks of chronic lung tissue exposure to insulin."

- check out the AP report